Source: GlobeNewswire

Press Release: Paratek : Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019

-- NUZYRA® (omadacycline) Net Sales increased 26% to $1.7 Million in the Second Quarter of 2019 -- -- Over 50% of Commercial Lives in U.S. now have Access to NUZYRA --

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Evan Loh's photo - CEO of Paratek


Evan Loh

CEO Approval Rating


Paratek is a biopharmaceutical company that develops antibiotic drugs to treat bacterial pneumonia in adults. Read more